Extracorporeal Life Support Devices

Extracorporeal Life Support Devices Market Outlook

The global Extracorporeal Life Support Devices market is projected to reach approximately USD 5.7 billion by 2035, exhibiting a remarkable compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. The growth of this market can be attributed to several key factors, including the rising incidence of respiratory and cardiac conditions, advancements in medical technology, and an increasing demand for organ transplantation procedures. The aging population across the globe is also contributing to the demand for extracorporeal life support systems, as older individuals are more susceptible to diseases that require such interventions. Furthermore, the increasing awareness among patients and healthcare professionals about the benefits of these devices is expected to drive market growth significantly. As healthcare facilities continue to invest in advanced medical infrastructure, the market for extracorporeal life support devices will likely experience substantial growth, particularly in developing regions.

Growth Factor of the Market

One of the primary growth factors for the Extracorporeal Life Support Devices market is the rising prevalence of chronic diseases, especially cardiovascular and respiratory disorders. With an increase in the number of patients requiring long-term support due to conditions such as heart failure and acute respiratory distress syndrome (ARDS), the demand for effective life support devices is surging. Additionally, technological advancements have led to the development of more sophisticated and efficient devices, which offer improved outcomes and patient comfort. These innovations, including the integration of artificial intelligence for monitoring and diagnostic purposes, are transforming the landscape of extracorporeal life support. The growing emphasis on disease management and prevention in healthcare systems is further propelling the market as healthcare providers strive to offer better treatment options. Moreover, the expanding healthcare infrastructure and increasing availability of specialized medical professionals are enhancing the accessibility of these devices, contributing to overall market growth.

Key Highlights of the Market

• The market is driven by increasing incidences of cardiac and respiratory diseases.
• Technological advancements are leading to the development of more efficient life support devices.
• Rising awareness among healthcare providers and patients about the benefits of extracorporeal life support systems.
• The growing geriatric population is contributing significantly to market demand.
• Emerging markets are witnessing rapid growth due to improving healthcare infrastructure.

By Product Type

Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)

Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is primarily utilized for patients with severe cardiac failure. It provides both cardiac and respiratory support by oxygenating the blood outside the body and then returning it to the arterial system. This device is frequently employed in critical care settings, especially for patients experiencing cardiogenic shock or recovering from cardiac surgery. The VA-ECMO market segment is expected to grow significantly due to the increasing prevalence of heart diseases and advancements in technology that allow for safer and more efficient procedures. Additionally, the growing awareness among healthcare professionals about the benefits and effectiveness of VA-ECMO will further bolster its adoption. Hospitals are increasingly integrating these devices into their critical care protocols, thereby enhancing the segment's growth potential.

Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO) is primarily used for patients suffering from severe respiratory failure, providing oxygenation while allowing for carbon dioxide removal. This form of life support is particularly beneficial for patients with conditions such as ARDS, where the lungs are unable to function effectively on their own. The VV-ECMO segment is witnessing a surge in demand due to the rising instances of severe respiratory diseases, including those exacerbated by environmental factors and viral infections. The ability of VV-ECMO to support patients during critical periods without requiring significant cardiac support positions it as a key component in modern respiratory care. Enhanced training programs for healthcare providers and improved protocols for the use of VV-ECMO are further driving growth in this segment.

Arterio-Venous Carbon Dioxide Removal (AVCO2R)

Arterio-Venous Carbon Dioxide Removal (AVCO2R) is an innovative technique specifically designed to remove carbon dioxide from the bloodstream, effectively addressing hypercapnia in critically ill patients. AVCO2R serves as a complementary treatment to traditional ECMO methods, primarily focusing on carbon dioxide clearance while minimizing the impact on oxygen levels. This technique is gaining traction in intensive care units, especially among patients with severe respiratory distress who require immediate intervention. The growing awareness of hypercapnia-related complications and advancements in AVCO2R technology, such as improved cannula designs and better monitoring systems, are propelling this segment's growth. Additionally, clinical studies supporting the efficacy of AVCO2R in enhancing patient outcomes are likely to increase adoption rates in hospitals worldwide.

Extracorporeal Cardiopulmonary Resuscitation (ECPR)

Extracorporeal Cardiopulmonary Resuscitation (ECPR) is a critical life-saving procedure that combines conventional CPR techniques with extracorporeal life support systems. This approach is particularly beneficial for patients experiencing cardiac arrest, as it provides immediate circulatory support and enhances the chances of survival. The ECPR segment is expected to experience considerable growth due to the increasing frequency of out-of-hospital cardiac arrests and the subsequent need for advanced resuscitation techniques. As healthcare providers become more trained in ECPR protocols, the integration of these systems into emergency medical services is expected to rise. Furthermore, ongoing research into the benefits of ECPR and successful case studies are likely to fuel its adoption in hospitals and emergency care settings.

Others

This category encompasses various extracorporeal life support devices that may not fit neatly into the aforementioned segments. These could include novel devices or new applications within the realm of extracorporeal support. Innovations in this space are continuously emerging as medical technology evolves and researchers explore new therapeutic avenues for critically ill patients. While this segment currently holds a smaller market share compared to the primary types, its growth potential is significant as healthcare providers seek alternative solutions to address complex medical conditions. The expansion of this category is also driven by ongoing technological developments and the increasing emphasis on personalization in patient care, leading to the emergence of customized support devices tailored to individual needs.

By Application

Respiratory Support

Respiratory support applications represent a significant portion of the extracorporeal life support devices market, particularly in the context of severe respiratory failure. Devices tailored for this application, such as VV-ECMO, are essential for managing conditions like ARDS, where traditional ventilation techniques may fail to meet patients’ oxygenation needs. The increasing prevalence of chronic respiratory diseases and emergent respiratory conditions, including those resulting from COVID-19, has led to heightened demand for respiratory support devices. Furthermore, advancements in technology, including more efficient oxygenation methods and reduced complication rates, have made extracorporeal devices a preferred choice in critical care. The continuous training of healthcare professionals in the use of these technologies and evidence from clinical studies supporting their efficacy are likely to enhance the segment's growth prospects.

Cardiac Support

Cardiac support applications are critical in the realm of extracorporeal life support, particularly for patients experiencing severe heart failure or those who have undergone complex cardiac surgeries. VA-ECMO systems are prominently featured in this segment, providing necessary circulatory support to sustain vital organ function during recovery. The growing burden of cardiovascular diseases, coupled with an increasing number of heart surgeries, is bolstering the demand for cardiac support devices. The integration of cardiac support systems into established treatment protocols in hospitals, along with advancements in device technology, is enhancing patient outcomes and survival rates. As the healthcare landscape continues to evolve, the emphasis on heart failure management and the development of specialized care teams are likely to drive further growth in this application segment.

Extracorporeal Cardiopulmonary Resuscitation (ECPR)

Extracorporeal Cardiopulmonary Resuscitation (ECPR) has become an increasingly vital application within the realm of life support devices, particularly in emergency medicine. ECPR is utilized in situations of sudden cardiac arrest, where rapid intervention is crucial for survival. The application of ECPR has been found to improve outcomes significantly, especially in cases where traditional resuscitation methods fail. The growing awareness of the efficacy of ECPR, along with advancements in training and technology, is fostering its adoption in emergency departments. As hospitals and emergency services continue to refine their protocols surrounding cardiac arrest scenarios, the ECPR application is likely to see substantial growth in the coming years, impacting the overall market positively.

Others

This category includes various applications of extracorporeal life support devices that do not fall strictly within the respiratory or cardiac support domains. These applications may involve novel therapeutic strategies, such as addressing complex metabolic disorders or providing support during specific surgical procedures. Innovations in this space are emerging as medical research continues to explore the potential benefits of extracorporeal support. While this segment currently represents a smaller share of the overall market, its growth prospects are promising, driven by increasing interest from healthcare providers in diverse applications for life support technologies. As more evidence-based research becomes available, the acceptance and usage of these devices in non-traditional applications are likely to expand.

By Distribution Channel

Hospitals

Hospitals constitute the primary distribution channel for extracorporeal life support devices, accounting for the majority of the market share. The increasing volume of critical care admissions, alongside the rising prevalence of cardiac and respiratory diseases, is driving demand for these devices in hospitals. Intensive care units (ICUs) are particularly reliant on advanced life support technologies to manage critically ill patients effectively. The establishment of specialized cardiac and respiratory care programs within hospitals further enhances the market for extracorporeal devices. Additionally, hospitals are investing in training and education for their healthcare staff to ensure the proper utilization and management of these complex systems, which is expected to positively influence market growth in this distribution channel.

Specialty Clinics

Specialty clinics are emerging as an important distribution channel for extracorporeal life support devices, particularly those focused on cardiac and respiratory care. As the demand for personalized and specialized medical services grows, many clinics are beginning to adopt advanced life support technologies to enhance patient outcomes. These clinics often provide targeted interventions for patients with specific conditions, such as heart failure or chronic obstructive pulmonary disease (COPD), making them suitable environments for extracorporeal support applications. The trend towards outpatient care and the increasing number of specialty clinics further support the growth of this channel in the market. As these facilities continue to expand their offerings and improve their technological capabilities, the adoption of extracorporeal life support devices is expected to rise.

Ambulatory Surgical Centers

Ambulatory surgical centers (ASCs) are becoming increasingly relevant in the distribution of extracorporeal life support devices, particularly for outpatient procedures that may require short-term support. With the increasing focus on minimizing hospital stays and enhancing patient convenience, ASCs are integrating advanced life support technologies into their practice. These facilities often handle a wide range of surgical procedures, and the availability of extracorporeal support devices can significantly improve patient safety during high-risk operations. As ASCs continue to evolve and expand their service offerings, the demand for extracorporeal life support devices is expected to increase, contributing to overall market growth. This shift towards outpatient care models is likely to open up new opportunities for manufacturers and providers in the life support sector.

Others

This category includes various non-traditional distribution channels for extracorporeal life support devices, which may encompass home healthcare, regional health networks, and telehealth services. As healthcare continues to evolve towards more patient-centric models, the incorporation of life support devices into these alternative settings is becoming increasingly feasible. For example, advancements in telemedicine and remote monitoring technologies may allow for the management of patients requiring extracorporeal support in non-institutional environments. As the landscape of healthcare changes and expands, these alternative distribution channels will likely play a more significant role in the overall market. The potential for home-based care or community health initiatives utilizing life support devices represents an exciting growth opportunity in the domain of extracorporeal life support.

By Patient Type

Pediatric

The pediatric patient segment is critical in the extracorporeal life support devices market, as children require specialized care and treatment modalities that differ significantly from adult patients. The use of extracorporeal support for pediatric patients typically addresses congenital heart defects, severe respiratory issues, and other critical conditions requiring immediate intervention. Advances in technology have led to the development of smaller, more adaptable devices that cater specifically to the unique anatomical and physiological characteristics of pediatric patients. Furthermore, increased awareness about the importance of timely intervention in pediatric emergencies is influencing demand for these devices. As healthcare providers continue to enhance their training and expertise in managing pediatric cases, the growth potential for extracorporeal life support devices in this segment is expected to expand considerably.

Adult

The adult patient segment is the largest contributor to the extracorporeal life support devices market, driven by the escalating prevalence of cardiovascular and respiratory conditions among adults. Adults often require advanced life support in critical situations involving cardiac arrest, acute respiratory failure, or post-surgical recovery. The increasing incidence of lifestyle-related diseases, coupled with a greater emphasis on the management of chronic conditions, has amplified the need for extracorporeal support systems. Furthermore, advancements in technology and the availability of specialized programs in hospitals are enhancing the efficacy of these devices in adult populations. As healthcare delivery continues to emphasize critical care for adults, the demand for extracorporeal life support devices will likely grow, resulting in sustained market expansion.

By Region

The regional analysis of the Extracorporeal Life Support Devices market indicates significant variations in adoption rates and growth potential across different geographic areas. North America holds a dominant position in the market, accounting for approximately 40% of the global share. The region benefits from advanced healthcare infrastructure, high prevalence rates of chronic diseases, and strong support for research and innovation in medical technology. Europe follows closely, driven by increasing investments in healthcare and a growing emphasis on critical care services. The market in Europe is expected to witness a CAGR of around 7% during the forecast period, fueled by advancements in device technology and a rising geriatric population.

Asia Pacific is emerging as a lucrative market for extracorporeal life support devices, projected to show robust growth due to improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced medical technologies. Countries like China and India are witnessing significant investments in healthcare facilities, contributing to a surge in demand for these devices. Latin America and the Middle East & Africa are also poised for growth, although they currently represent a smaller share of the market compared to North America and Europe. Initiatives aimed at enhancing healthcare access and quality in these regions are likely to foster the adoption of extracorporeal life support systems in the near future.

Opportunities

The opportunities in the Extracorporeal Life Support Devices market are vast, particularly due to the continuous evolution of medical technology. As healthcare providers increasingly adopt advanced technologies, including automation and artificial intelligence, the potential for developing new, more efficient devices is significant. This technological evolution is likely to enhance patient outcomes and streamline workflows in critical care settings, making extracorporeal support more accessible. Moreover, there is growing interest in expanding the applications of these devices beyond traditional settings, such as in outpatient facilities and home care environments. This shift opens up potential partnerships between manufacturers and healthcare providers to develop tailored solutions that can cater to a wider range of patient needs, thus unlocking new revenue streams.

Additionally, the global focus on improving healthcare access and reducing mortality rates associated with critical illnesses presents significant opportunities for market players. Governments and health organizations are increasingly investing in healthcare infrastructure, particularly in emerging economies, creating a conducive environment for the deployment of extracorporeal life support devices. The rising prevalence of lifestyle diseases, coupled with an aging population, indicates a sustained demand for life support technologies. Companies that can innovate and address the specific needs of these diverse patient populations, while maintaining affordability and accessibility, are well-positioned to capitalize on the growing market potential. With ongoing research into new treatment modalities and device applications, the future of the extracorporeal life support devices market is promising.

Threats

The Extracorporeal Life Support Devices market faces several threats that could impact its growth trajectory. One of the primary threats is the high cost associated with the acquisition and maintenance of these advanced devices, which can pose a barrier for smaller healthcare facilities and developing regions. This financial strain may lead to disparities in access to essential life support technologies, ultimately affecting patient outcomes. Additionally, the complexity of these systems requires specialized training for healthcare providers, and any shortage of skilled professionals could hinder the effective implementation of extracorporeal support strategies. Adverse events and complications associated with the use of these devices, although relatively rare, could also lead to increased scrutiny and regulatory challenges, further impacting adoption rates.

Moreover, the emergence of alternative treatment modalities and methodologies poses a potential threat to the market. As healthcare continuously evolves, new innovations may disrupt established practices, thereby affecting the demand for traditional extracorporeal life support devices. For instance, advancements in pharmacological treatments or minimally invasive techniques may reduce reliance on these systems in some cases. Thus, manufacturers must remain vigilant and adaptable to the shifting healthcare landscape to maintain their market position and relevance. Continuous innovation, rigorous clinical testing, and strong clinical evidence demonstrating the efficacy and safety of extracorporeal life support devices will be essential in mitigating these threats.

Competitor Outlook

• Maquet Getinge Group
• Medtronic plc
• Terumo Cardiovascular Systems Corporation
• Fresenius SE & Co. KGaA
• CardiacAssist, Inc.
• Hemovent GmbH
• Xenios AG
• Abiomed, Inc.
• LivaNova PLC
• ECMO, Inc.
• Getinge Group
• Auxocell Laboratories, Inc.
• Novalung GmbH
• AngioDynamics, Inc.
• VAXCIS, Inc.

The competitive landscape of the Extracorporeal Life Support Devices market is characterized by a diverse array of companies working to innovate and expand their product offerings. Major players such as Maquet Getinge Group and Medtronic plc are at the forefront, continually investing in research and development to enhance the efficacy and safety of their devices. These companies are leveraging advanced technologies to create more user-friendly and adaptable systems to meet the growing demand in critical care settings. Other notable players, including Terumo Cardiovascular Systems Corporation and Fresenius SE & Co. KGaA, are also focusing on expanding their product portfolios through strategic partnerships and collaborations to gain a competitive edge in the market.

In addition to established manufacturers, several emerging companies are innovating within the Extracorporeal Life Support Devices space, aiming to address the specific needs of patients and healthcare providers. Companies like Hemovent GmbH and Xenios AG are developing cutting-edge technologies to improve patient outcomes and streamline the use of life support systems. These emerging players are capitalizing on niche market opportunities and exploring novel applications for their devices, which enhances competition and drives overall market growth. As newer entrants continue to emerge, the competitive dynamics of the market are expected to evolve, leading to an increasingly diverse and innovative environment.

As competition intensifies, companies are also focusing on mergers and acquisitions to strengthen their market positions and expand their reach. Collaborations between established players and startups are becoming increasingly common, fostering innovation and the rapid introduction of groundbreaking technologies to the market. With the growing emphasis on personalized healthcare and tailored treatment strategies, the landscape of the Extracorporeal Life Support Devices market is set to continue evolving. To remain competitive, organizations will need to prioritize continuous improvement, regulatory compliance, and effective marketing strategies aimed at educating healthcare providers about the benefits of their devices.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Xenios AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 ECMO, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 LivaNova PLC
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 VAXCIS, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Abiomed, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Getinge Group
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hemovent GmbH
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Medtronic plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Novalung GmbH
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 AngioDynamics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 CardiacAssist, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Maquet Getinge Group
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fresenius SE & Co. KGaA
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Auxocell Laboratories, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Terumo Cardiovascular Systems Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Extracorporeal Life Support Devices Market, By Application
    • 6.1.1 Respiratory Support
    • 6.1.2 Cardiac Support
    • 6.1.3 Extracorporeal Cardiopulmonary Resuscitation (ECPR)
    • 6.1.4 Others
  • 6.2 Extracorporeal Life Support Devices Market, By Patient Type
    • 6.2.1 Pediatric
    • 6.2.2 Adult
  • 6.3 Extracorporeal Life Support Devices Market, By Product Type
    • 6.3.1 Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
    • 6.3.2 Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
    • 6.3.3 Arterio-Venous Carbon Dioxide Removal (AVCO2R)
    • 6.3.4 Extracorporeal Cardiopulmonary Resuscitation (ECPR)
    • 6.3.5 Others
  • 6.4 Extracorporeal Life Support Devices Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Extracorporeal Life Support Devices Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Extracorporeal Life Support Devices market is categorized based on

By Product Type

• Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
• Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
• Arterio-Venous Carbon Dioxide Removal (AVCO2R)
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)
• Others

By Application

• Respiratory Support
• Cardiac Support
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Patient Type

• Pediatric
• Adult

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Maquet Getinge Group
• Medtronic plc
• Terumo Cardiovascular Systems Corporation
• Fresenius SE & Co. KGaA
• CardiacAssist, Inc.
• Hemovent GmbH
• Xenios AG
• Abiomed, Inc.
• LivaNova PLC
• ECMO, Inc.
• Getinge Group
• Auxocell Laboratories, Inc.
• Novalung GmbH
• AngioDynamics, Inc.
• VAXCIS, Inc.